

AMC BROADGATE QUANT 1

As of 30 November 2025

OBJECTIVE

To efficiently harvest rewarded systematic risk premia in the market, while eliminating unrewarded risk exposures, allowing investors to earn higher returns per unit of risk.

INVESTMENT STRATEGY & PROCESS

The portfolio is based on Broadgate's Quantitative Multi-Factor Model. It focuses on the proper management of "factor exposures" as the main source of performance and looks through asset class decompositions to focus on underlying factor decomposition. It aims to invest in an equal-weighted portfolio of 40 equity names in developed markets, selected based on Broadgate's proprietary Multi-Factor model. The strategy aims to outperform the benchmark – MSCI World index – by following an allocation determined by the intensity of factors (Momentum, Value, Low Volatility, Quality and Growth). Factors are built in-house, using proprietary descriptors with high return explanatory powers and a unique weighting scheme that allocates dynamically among the factors. The portfolio is rebalanced monthly, and the methodology is continuously reviewed by Broadgate's quant research team.

PRODUCT CHARACTERISTICS

Product	> AMC Broadgate Quant 1
ISIN	> FRELU0003488
Issuer/ Guarantor	Exane Solutions Luxembourg (SA) / BNP Paribas Moody's: Aa3; S&P: A+; Fitch AA-
Underlying	> Broadgate Quant 1 Dynamic Portfolio
Actively Managed	Yes, by Broadgate Advisers
Maturity	➤ Open-End
Denomination	▶ 1'000 USD
Currency	> USD
Total Management Fees	 1.25% p.a. (i.e 0.25% to Exane Solutions and 1.00% to Broadgate Advisers) + 10% Performance fees based on high watermark over an initial hurdle of 107%
Liquidity	> Daily
Pricing Publication	> Telekurs, Bloomberg
NAV	➤ USD 1297.09 (as of November 30 th , 2025)

AMC Manager Comment

The strategy was up 1.4% in November, while the MSCI World was up 0.2%.

Attribution: Sector performance was mixed during the month, with *Health Care* (8.2%) and *Materials* (4.0%) leading, while *Information Technology* (-4.7%) and *Consumer Discretionary* (-1.6%) lagged. The *Broadgate Quant* mandate overperformed the market by 1..2%, driven by both positive selection (0.75%) and allocation (0.51%) effects.

The positive allocation effect came from overweight positions in *Health Care and Materials*, which were the best-performing sectors, while the positive selection effect was mainly attributable to *Eli Lilly (24.8%)*, *Fresnillo (19.5%)*, *Jack Henry & Associates (17.1%)*, and *Wheaton Precious Metals (14.0%)*.

Factor Sensitivity (Beta): The current top style exposures are, by order, Momentum, Quality, and Growth.

HISTORICAL PERFORMANCE

Cumulative Performance (basis USD) 50% 40% 30% 20% 10% -20% -30% Sep-21 Aug-22 Jul-23 Jun-24 May-25 Broadgate Quant 1* MSCI World *Net of fees.

Performance snapshot of the share class - Actual 15.09.21 - 30.11.25

		Quant 1*	World
Performance (%)	1 Month	1.44	0.18
	3 Months	5.41	5.28
	YTD	16.39	18.63
	Since Inception	29.71	40.63
Risk (ex-post)	Annualized Volatility (%)	17.69	16.82
	Correlation	0.89	
	Tracking Error (%)	8.08	
	Beta	0.94	
Risk/Return	Sharpe Ratio	0.40	0.52
	Information Ratio	-	

AMC Broadgate Quant 1

Broadgate



AMC BROADGATE QUANT 1

As of 30 November 2025









Portfolio Contribution

Best Performers


Components	MTD Performance
ELI LILLY & CO	24.82%
FRESNILLO PLC	19.54%
JACK HENRY & ASSOCIATES INC	17.15%
ALPHABET INC-CL A	15.84%
WHEATON PRECIOUS METALS CORP	14.07%
MERCK & CO. INC.	12.82%
NEWMONT CORP	12.36%
MONSTER BEVERAGE CORP	12.21%
INCYTE CORP	11.75%
HARTFORD INSURANCE GROUP INC	10.35%

Worst Performers


Components	MTD Performance
ARISTA NETWORKS INC	-17.13%
NVIDIA CORP	-12.59%
PAYCOM SOFTWARE INC	-11.21%
EMCOR GROUP INC	-8.27%
MONOLITHIC POWER SYSTEMS INC	-7.64%
F5 INC	-7.53%
BROADCOM INC	-7.35%
CADENCE DESIGN SYS INC	-7.02%
AUTO TRADER GROUP PLC	-6.74%
KLA CORP	-6.16%

Portfolio Allocations

Breakdown by Geography



Breakdown by Sector



For more Information:

Broadgate Advisers

Tel: +41 (0)22 316 0060 Email: Quant1@broadgate.ch Internet: https://broadgateadvisers.com/

BNP Paribas Suisse SA

Email: joris.maillet@bnpparibas.com

This document/communication may contain "Research" as defined under MFID II unbundling rules; any such Research is intended either (i) for those firms who are in scope of the MFID II unbundling rules and have signed up to a BNP Paribas Global Markets Research package, or (ii) for firms that are out of scope of the MFID II unbundling rules and therefore are not required to pay for Research under MFID II. Please note that it is your firm's responsibility to ensure that you do not view or use any Research in this document. If your firm has not signed up to a BNP Paribas Global Markets Research package, unless your firm is out of scope of the MFID II unbundling rules. This document may also be regarded as a minor non-monetary benefit (MNMB) and it is your firm's responsibility to consider its own regulatory obligations in relation to inducements and accepting MNMBs. This document is considering the communication and has been prepared by a Sales and Marketing function within BNP Paribas and (in the substitution of the Sales and Marketing function within BNP Paribas and (in the substitution of the Sales and Marketing function within BNP Paribas within the comment of the substitution of the sub